secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001104659-23-063884
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports ELX-02 Phase 2 topline: one patient remission; opens $50M ATM offering
--------------------------------------------------------------------------------

- One of two completed patients achieved remission (≥50% UPCR decline); five of eight readings averaged 53% below baseline.
- Second patient showed no significant UPCR change; both had same Col4A4 mutation but different RAAS inhibitor levels.
- ELX-02 generally well tolerated; no discontinuations; kidney biopsies showed no nephrotoxicity.
- Entered ATM agreement with Oppenheimer for up to $50M common stock sales, currently limited to $6.5M due to S-3 limits.
- Prior SVB Leerink ATM agreement terminated; no shares were sold under that agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/0001104659-23-063884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923063884/tm2316480d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-063884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer